What is Soligenix's stock price target for 2024?

0 analysts have issued 12-month price objectives for Soligenix's stock. Their SNGX share price targets range from $3.00 to $3.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 535.6% from the stock's current price. View analysts price targets for SNGX or view top-rated stocks among Wall Street analysts .

How have SNGX shares performed in 2024?

Soligenix's stock was trading at $0.7572 at the start of the year. Since then, SNGX stock has decreased by 37.7% and is now trading at $0.4720. View the best growth stocks for 2024 here .

Are investors shorting Soligenix?

Soligenix saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 115,800 shares, an increase of 71.0% from the March 15th total of 67,700 shares. Based on an average trading volume of 272,900 shares, the short-interest ratio is presently 0.4 days. Currently, 1.1% of the shares of the company are short sold. View Soligenix's Short Interest .

When is Soligenix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SNGX earnings forecast .

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) announced its quarterly earnings data on Friday, March, 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. The biopharmaceutical company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.20 million. Soligenix had a negative net margin of 731.94% and a negative trailing twelve-month return on equity of 251.07%.

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV) , T2 Biosystems (TTOO) , Trevena (TRVN) , Vaxart (VXRT) , OPKO Health (OPK) , SCYNEXIS (SCYX) , Dynavax Technologies (DVAX) , Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM) .

How do I buy shares of Soligenix?

Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SNGX

Soligenix (SNGX) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free SNGX Stock Alerts

$0.47

0.00 (0.00%)

(As of 04/16/2024 ET)

Compare

Today's Range: $0.46
▼
$0.61
50-Day Range: $0.39
▼
$0.82
52-Week Range: $0.37
▼
$4.20

Volume: 8.98 million shs
Average Volume: 3.06 million shs
Market Capitalization: $4.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Get Soligenix alerts:

Soligenix MarketRank™ Stock Analysis

Analyst Rating: 0.00 Rating Score
Upside/Downside: 535.6% Upside
$3.00 Price Target
Short Interest: Healthy
1.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.63
Based on 15 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From $0.81 to ($0.68) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.34 out of 5 stars

2.0

Analyst's Opinion

Amount of Analyst Coverage
Soligenix has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.10% of the float of Soligenix has been sold short.
Short Interest Ratio / Days to Cover
Soligenix has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Soligenix has recently increased by 71.05%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Soligenix does not currently pay a dividend.
Dividend Growth
Soligenix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNGX.

2.0

News and Social Media Coverage

News Sentiment
Soligenix has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Soligenix this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for SNGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Soligenix to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Soligenix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.36% of the stock of Soligenix is held by insiders.
Percentage Held by Institutions
Only 3.60% of the stock of Soligenix is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Soligenix are expected to decrease in the coming year, from $0.81 to ($0.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Soligenix is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Soligenix is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Soligenix has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Soligenix Stock (NASDAQ:SNGX)

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase IIa clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

SNGX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SNGX Stock News Headlines

April 16, 2024 | finanznachrichten.de

SOLIGENIX, INC.: FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

April 15, 2024 | finance.yahoo.com

Why Is Penny Stock Soligenix Trading Higher On Monday?

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

April 15, 2024 | proactiveinvestors.com

Soligenix surges as MarVax vaccine secures Orphan Drug Designation from FDA

April 15, 2024 | marketwatch.com

Soligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDA

April 15, 2024 | markets.businessinsider.com

Soligenix's MarVax Gets Orphan Drug Designation

April 15, 2024 | msn.com

Soligenix stock soars 106% on FDA orphan drug status

April 15, 2024 | investorplace.com

Why Are Stocks Up Today?

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

April 15, 2024 | investorplace.com

Why Is Soligenix (SNGX) Stock Up 58% Today?

April 15, 2024 | finance.yahoo.com

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

April 11, 2024 | msn.com

Solinex Down On Orphan Drug Designation

April 11, 2024 | finance.yahoo.com

SNGX: Agreement with EMA on Second Confirmatory Trial for HyBryte™…

April 11, 2024 | markets.businessinsider.com

Soligenix's SuVax Granted FDA Orphan Drug Designation For Prevention Of Sudan Ebolavirus Infection

April 11, 2024 | prnewswire.com

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

April 3, 2024 | prnewswire.com

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency

March 20, 2024 | finance.yahoo.com

SNGX: Discussions Continue with FDA Regarding Second Phase 3 Study for HyBryte™ in CTCL…

March 15, 2024 | investorplace.com

SNGX Stock Earnings: Soligenix Beats EPS, Beats Revenue for Q4 2023

March 15, 2024 | benzinga.com

Recap: Soligenix Q4 Earnings

March 15, 2024 | prnewswire.com

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

February 8, 2024 | finance.yahoo.com

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

February 1, 2024 | thestreet.com

Soligenix Inc.

January 26, 2024 | finanznachrichten.de

Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV

January 26, 2024 | finance.yahoo.com

Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

January 25, 2024 | finance.yahoo.com

Soligenix to Present at The Microcap Conference

January 10, 2024 | finance.yahoo.com

SNGX: Phase 2a Psoriasis Trial Achieves Clinical Success…

January 8, 2024 | marketwatch.com

Soligenix Shares Rise 8% After SGX945 Gets FDA Fast Track Designation

See More Headlines

Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/15/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SNGX
CUSIP: N/A
CIK: 812796
Web: www.soligenix.com
Phone: (609) 538-8200
Fax: 609-452-6467
Employees: 13
Year Founded: 1987

Price Target and Rating

Average Stock Price Target: $3.00
High Stock Price Target: $3.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +476.4%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.90)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 0.64
P/E Growth: N/A
Net Income: $-6,140,000.00
Net Margins: -731.94%
Pretax Margin: -942.67%
Return on Equity: -251.07%
Return on Assets: -49.94%

Debt

Debt-to-Equity Ratio: 0.40
Current Ratio: 1.55
Quick Ratio: 1.52

Sales & Book Value

Annual Sales: $840,000.00
Price / Sales: 6.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.24 per share
Price / Book: 2.17

Miscellaneous

Outstanding Shares: 10,520,000
Free Float: 10,381,000
Market Cap: $5.48 million
Optionable: Not Optionable
Beta: 1.81

Social Links

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Christopher J. Schaber Ph.D. (Age 58)
Chairman of the Board of Directors, CEO & President
Comp: $625k
Mr. Jonathan L. Guarino CPA (Age 51)
CGMA, Senior VP, CFO & Corporate Secretary
Comp: $309.4k
Dr. Oreola Donini Ph.D. (Age 52)
Senior VP & Chief Scientific Officer
Comp: $342.31k
Dr. Richard C. Straube M.D. (Age 72)
MSc., Senior VP & Chief Medical Officer
Comp: $212.2k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SNGX Stock Analysis - Frequently Asked Questions

What is Soligenix's stock price target for 2024?: 0 analysts have issued 12-month price objectives for Soligenix's stock. Their SNGX share price targets range from $3.00 to $3.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 535.6% from the stock's current price.
View analysts price targets for SNGX or view top-rated stocks among Wall Street analysts.
How have SNGX shares performed in 2024?: Soligenix's stock was trading at $0.7572 at the start of the year. Since then, SNGX stock has decreased by 37.7% and is now trading at $0.4720.
View the best growth stocks for 2024 here.
Are investors shorting Soligenix?: Soligenix saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 115,800 shares, an increase of 71.0% from the March 15th total of 67,700 shares. Based on an average trading volume of 272,900 shares, the short-interest ratio is presently 0.4 days. Currently, 1.1% of the shares of the company are short sold.
View Soligenix's Short Interest.
When is Soligenix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SNGX earnings forecast.

How were Soligenix's earnings last quarter?: Soligenix, Inc. (NASDAQ:SNGX) announced its quarterly earnings data on Friday, March, 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. The biopharmaceutical company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.20 million. Soligenix had a negative net margin of 731.94% and a negative trailing twelve-month return on equity of 251.07%.
What other stocks do shareholders of Soligenix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).
How do I buy shares of Soligenix?: Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNGX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial